NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.65
-0.15 (-3.95%)
▼
5d:
-12.47%
30d:
-22.83%
90d:
-28.99%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
NAGE is down 14.0% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 43 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NAGE is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NAGE is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.12
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.52
51.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.65, which is considered oversold relative to its 30-day fair value range of $4.16 to $4.95. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.0) compared to its historical average (20.4). Remarkably, the market is currently pricing in an annual earnings decline of 16.3% over the next few years. This pessimistic expectation contrasts with the company's recent 16.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.60 (+245.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $3.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.60 (+245.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.16 -
$4.95
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding NAGE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.9%)
- BULLISH: Trading 245.2% below Wall St target ($12.60)
- WARNING: Recommendation downgraded due to -12.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.16 -
$4.95
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.67
Resistance Level
$5.12
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.97
Wall Street Target
$12.60
(+245.2%)
Revenue Growth (YoY)
3.3%
Earnings Growth (YoY)
16.7%
Profit Margin
14.3%
Valuation Discount vs History
-16.3% cheaper
PE vs Historical
12.0 vs 20.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.3%
(market-implied from PE analysis)
1-Year Target
$3.29
(-10%)
2-Year Target
$2.96
(-19%)
3-Year Target
$2.66
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→20)
$4.54
(+24%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 32.6%)
$15.70
(+330%)
Base:
(SPY PE: 12.0, Growth: 32.6%)
$8.51
(+133%)
Bear:
(PE: 10.2, Growth: 32.6%)
$7.23
(+98%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 18.10 | Current EPS (TTM): $0.21
Bull Case
$6.07
(+66%)
Analyst growth 45.2%, PE expands to 19.9
Base Case
$5.52
(+51%)
Market implied 45.2%, PE stable at 18.1
Bear Case
$2.58
(-29%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.0 to 20.4
Stabilization Target:
$6.22
(+70.5%)
PE Expansion Potential:
+70.5%
Share & Embed Analysis
Last updated: May 15, 2026 7:20 PM ET
Data refreshes hourly during market hours. Next update: 8:20 PM
Data refreshes hourly during market hours. Next update: 8:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 55 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 57 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
